{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-016230","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.075963+00:00","generated_at":"2026-05-15T15:49:58.695406+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Esperion Q4 rev $168.4M (+144% Y/Y); FY25 rev $403.1M; Q4 net income $61.8M; acquires Corstasis","bullets":["U.S. net product revenue Q4 $43.7M (+38% Y/Y); FY25 $159.6M (+38% Y/Y).","Collaboration revenue Q4 $124.7M (includes $90M Otsuka milestone); FY25 $243.6M (+12% Y/Y).","Q4 net income $61.8M ($0.26 basic EPS vs loss $0.11 in Q4 2024); FY25 net loss $22.7M narrowed from $51.7M.","Agreed to acquire Corstasis Therapeutics (Enbumyst nasal spray for CHF edema); targets $4B U.S. market.","Patent settlements restrict generic entry until April 2040; FY26 opex guidance $225-255M (incl ~$15M non-cash)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-016230","json":"https://secwatch.observer/filing/0001628280-26-016230.json","markdown":"https://secwatch.observer/filing/0001628280-26-016230.md","text":"https://secwatch.observer/filing/0001628280-26-016230.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026016230/0001628280-26-016230-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026016230/espr-20260310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T15:49:58.695406+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}